GSK plc, Pfizer and Shionogi Complete Changes to ViiV Healthcare Shareholding

GSK plc and Shionogi & Co., Ltd. announced the completion of a transaction that alters the shareholding in ViiV Healthcare Limited. Pfizer Inc. has exited its investment, with Shionogi increasing its economic interest to 21.7% and GSK maintaining a 78.3% majority share. The transaction involved ViiV Healthcare issuing new shares to Shionogi for $2.125 billion and canceling Pfizer's holding. Pfizer received $1.875 billion, and GSK received a special dividend of $0.250 billion. The Pfizer put option liability previously shown in GSK's accounts was extinguished through retained earnings. This filing is an update on the shareholding changes within ViiV Healthcare, a specialist HIV company.